[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@Franca_ole Franca_ole
Franca_ole posts on X about $4503t, $sgmo, $sgmos, $730m the most. They currently have XXX followers and XXX posts still getting attention that total XX engagements in the last XX hours.
Engagements: XX #
- X Week XXXXX +694%
- X Month XXXXXX -XX%
- X Months XXXXXXX +1.80%
- X Year XXXXXXX +915%
Mentions: X #
- X Months XX -XX%
- X Year XXX +323%
Followers: XXX #
- X Week XXX +0.75%
- X Month XXX +4.40%
- X Months XXX +25%
- X Year XXX +76%
CreatorRank: undefined #
Social Influence #
Social category influence countries
Social topic influence $4503t, $sgmo, $sgmos, $730m, $1900share, $zimv, japan
Top Social Posts #
Top posts by engagements in the last XX hours
"@BiotechAnalysst Astellas is expanding its activities in the field of gene therapy for neurological diseases particularly through Astellas Gene Therapies. Access to $SGMO's STAC-BBB is crucial for this"
@Franca_ole on X 2025-07-17 21:23:04 UTC XXX followers, XXX engagements
"@BiotechAnalysst Astellas invests heavily in innovation and biotechnology partnerships for example through acquisitions and collaborations with biotech companies in order to gain access to new technologies" @Franca_ole on X 2025-07-17 20:50:18 UTC XXX followers, XXX engagements
"$ZIMV to be acquired by ARCHIMED for $19.00/share in cash ($730M EV) representing a XX% premium to 90-day VWAP; deal reflects ARCHIMEDs strategic healthcare focus" @Franca_ole on X 2025-07-21 12:39:45 UTC XXX followers, XXX engagements
"Since signing the license agreement with $SGMO Astellas has exclusive rights to STAC-BBB a neurotropic AAV capsid with high blood-brain barrier penetration for the treatment of up to five neurological target diseases. Sangamo received $XX million upfront and could earn up to $XXX billion in milestone payments and royalties" @Franca_ole on X 2025-07-17 21:26:06 UTC XXX followers, XXX engagements
"Who knows maybe $SGMO will start licensing ST-920 in Asia for example in Japan. An additional cash injection would be good for the company in the current situation. "This finding highlights a critical need for improvements in patient-physician communication and increased medical education about Fabry disease in Japan the researchers wrote."" @Franca_ole on X 2025-07-17 17:12:36 UTC XXX followers, 2015 engagements